These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34278611)

  • 1. Durability and delayed treatment effects of zoledronic acid on bone loss after spinal cord injury: a randomized, controlled trial.
    Edwards WB; Haider IT; Simonian N; Barroso J; Schnitzer TJ
    J Bone Miner Res; 2021 Nov; 36(11):2127-2138. PubMed ID: 34278611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.
    Shapiro J; Smith B; Beck T; Ballard P; Dapthary M; BrintzenhofeSzoc K; Caminis J
    Calcif Tissue Int; 2007 May; 80(5):316-22. PubMed ID: 17417700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
    Adachi JD; Lyles KW; Colón-Emeric CS; Boonen S; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Bucci-Rechtweg C; Su G; Eriksen EF; Magaziner JS
    Osteoporos Int; 2011 Sep; 22(9):2539-49. PubMed ID: 21249332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of zoledronic acid in the management of osteoporosis.
    Maricic M
    Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.
    Bubbear JS; Gall A; Middleton FR; Ferguson-Pell M; Swaminathan R; Keen RW
    Osteoporos Int; 2011 Jan; 22(1):271-9. PubMed ID: 20358358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study.
    Bauman WA; Cirnigliaro CM; La Fountaine MF; Martinez L; Kirshblum SC; Spungen AM
    J Bone Miner Metab; 2015 Jul; 33(4):410-21. PubMed ID: 25158630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women.
    Bai H; Jing D; Guo A; Yin S
    J Int Med Res; 2013 Jun; 41(3):697-704. PubMed ID: 23669294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study.
    Oleson CV; Marino RJ; Formal CS; Modlesky CM; Leiby BE
    Spinal Cord; 2020 Aug; 58(8):921-929. PubMed ID: 32055041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
    Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA;
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability.
    Crack LE; Haider IT; Simonian N; Barroso J; Gabel L; Schnitzer TJ; Edwards WB
    Osteoporos Int; 2023 Sep; 34(9):1637-1645. PubMed ID: 37289320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.
    Ofotokun I; Titanji K; Lahiri CD; Vunnava A; Foster A; Sanford SE; Sheth AN; Lennox JL; Knezevic A; Ward L; Easley KA; Powers P; Weitzmann MN
    Clin Infect Dis; 2016 Sep; 63(5):663-671. PubMed ID: 27193748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
    Silverman SL; Kriegman A; Goncalves J; Kianifard F; Carlson T; Leary E
    Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study.
    Eastell R; Boonen S; Cosman F; Reid IR; Palermo L; Cummings SR; Black DM
    J Bone Miner Res; 2015 Mar; 30(3):570-4. PubMed ID: 25214069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
    Black DM; Reid IR; Napoli N; Ewing SK; Shiraki M; Nakamura T; Takeuchi Y; Schafer AL; Kim TY; Cauley JA
    J Bone Miner Res; 2022 Jan; 37(1):21-28. PubMed ID: 34585443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between timing of zoledronic acid infusion and hip fracture healing.
    Colón-Emeric C; Nordsletten L; Olson S; Major N; Boonen S; Haentjens P; Mesenbrink P; Magaziner J; Adachi J; Lyles KW; Hyldstrup L; Bucci-Rechtweg C; Recknor C;
    Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.